Neostigmine/glycopyrronium bromide
Combination of
NeostigmineCholinesterase inhibitor
Glycopyrronium bromideAntimuscarinic agent
Clinical data
Trade namesPrevduo
Other namesNeostigmine methylsulfate/glycopyrrolate, glycopyrronium bromide/neostigmine metilsulfate
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status

Neostigmine/glycopyrronium bromide, sold under the brand name Prevduo , is a fixed-dose combination medication used for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.[2] It contains neostigmine as the methylsulfate, a cholinesterase inhibitor, and glycopyrronium bromide, an antimuscarinic agent.[2]

Neostigmine/glycopyrronium bromide was approved for medical use in the United Kingdom in 2007,[1] and in the United States in February 2023.[3]

Medical uses

Neostigmine/glycopyrronium bromide is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following non-depolarizing neuromuscular blocking agent reversal administration.[3]

References

  1. ^ a b "Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for Injection - Summary of Product Characteristics (SmPC)". (emc). 12 November 2018. Archived from the original on 7 August 2022. Retrieved 25 February 2023.
  2. ^ a b c "Archived copy" (PDF). Archived (PDF) from the original on 26 February 2023. Retrieved 25 February 2023.((cite web)): CS1 maint: archived copy as title (link)
  3. ^ a b https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216903Orig1s000ltr.pdf Archived 26 February 2023 at the Wayback Machine Public Domain This article incorporates text from this source, which is in the public domain.


Categories